Key result
Intravenous doxorubicin administration was associated with local urticaria in 10 patients and generalized urticaria in 1 patient, which does not appear to contraindicate further treatment.
Why the study?
Does intravenous doxorubicin administration cause urticaria in patients with malignant neoplasms?
Observational (n=11)
Does intravenous doxorubicin administration cause urticaria in patients with malignant neoplasms?
Urticaria following doxorubicin administration is generally localized and does not necessarily contraindicate further treatment under close observation.
Answers are grounded in this paper and cite their sources.
Urticaria may not contraindicate doxorubicin continuation; hypothesis-generating case data leave incidence and management open for prospective study.
Urticaria developed above the site of injection with doxorubicin hydrochloride in 11 patients with malignant neoplasms. Generalized urticaria without anaphylaxis developed in one patient, while only local reactions developed in the other ten. A reaction developed in two patients on their first exposure to doxorubicin. Two of the seven patients who received subsequent doxorubicin therapy had further reactions. Urticaria does not seem to be a contraindication to further treatment with doxorubicin if the patient is closely observed. The value of prophylactic antihistamines of corticosteroids is not clear.
No takes yet. Share an insight, caveat, or question.
Luís Souhami (1978) conducted an observational in Malignant neoplasms (n=11). Intravenous doxorubicin was evaluated on Development of urticaria. Intravenous doxorubicin administration was associated with local urticaria in 10 patients and generalized urticaria in 1 patient, which does not appear to contraindicate further treatment.
Synapse has enriched 10 related papers. Consider them for comparative context: